Host factors, inflammation, and HIV associated TB
宿主因素、炎症和 HIV 相关结核病
基本信息
- 批准号:9114703
- 负责人:
- 金额:$ 81.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-01 至 2017-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeActivities of Daily LivingAffectAftercareAntigensAntitubercular AgentsArchivesBiological MarkersCCR5 geneCCR6 geneCD4 Positive T LymphocytesCD8B1 geneCXCR3 geneCause of DeathCell CountCellsCharacteristicsClinicalContainmentDataDiseaseEnvironmentEpigenetic ProcessEpitopesFrequenciesFutureGrowthHIVHIV-1HealthImmuneImmune responseImmune systemIndividualInfectionInflammationIntegration Host FactorsInterleukin-5LeadLinkLong-Term EffectsLungLung diseasesMediatingMemoryMycobacterium tuberculosisMycobacterium tuberculosis antigensOutcomePatientsPeripheralPeripheral Blood Mononuclear CellPersonsPhasePlayRNARandomized Clinical TrialsRandomized Controlled TrialsRecording of previous eventsRelapseRelative (related person)RiskRoleSELL geneSamplingStagingSyndromeT cell responseT-Cell ActivationT-Cell DevelopmentT-LymphocyteTestingTh1 CellsTimeTreatment ProtocolsTreatment outcomeTropismTuberculosisViralVirusabstractingantiretroviral therapybaseco-infectioncohortepigenetic markerexperienceimmunosuppressedimprovedin vitro Assayinsightmemory CD4 T lymphocytemonocytemortalitynovelperipheral bloodpreventreconstitutionresearch studyresponseterminally differentiated effector memory (TEM) T cellstuberculosis treatmentvaccine development
项目摘要
DESCRIPTION (provided by applicant):
Although infection with Mycobacterium tuberculosis (MTb) is the largest cause of death in AIDS, and it is the major cause of HIV-associated pulmonary disease globally, little is known about how TB co-infection impacts long term immune reconstitution or the HIV-1 reservoir. The Cambodian Early vs. Late Introduction of Anti- retrovirals (ART) (CAMELIA) randomized clinical trial showed that early initiation of ART (2 weeks after TB therapy initiation versus late ART at 8
weeks), resulted in a significant (34%) decrease in mortality in TB+/HIV+ patients with a CD4+ T cell count <200 cells/mm, a survival benefit that persisted for at least 3 years. Our preliminary data examining T cell responses in TB+/HIV+ individuals from the CAMELIA randomized clinical trial in a nested substudy, demonstrated that TB and TB-associated immune reconstitution syndrome (TB-IRIS) results in profound changes in the T cell compartment for at least 8 months after treatment initiation. For example, TB co-infection and TB-IRIS is associated with massive T cell activation including elevated CCR5+ T cells and results in significant impact on the proportions of central memory (TCM) (CD62L+CD45RA-) CD4+T cells, the major peripheral HIV reservoir component and effector memory. In patients who experienced TB- IRIS, we observed a reciprocal expansion of T effector (TEM) (CD62L-CD45RA-) CD4+T cells, which are associated with control TB. Furthermore, TB-IRIS patients had elevated CXCR3+CCR6+CD4+ T cells, which are thought to mediate a large portion of CD4+ anti-TB responses, and these CXCR3+CCR6+CD4+ T cells remained significantly elevated for at least 8 months after the initiation of ART. Based on our preliminary data, we hypothesize that the distinct cellular responses we observed in TB-IRIS may represent important protective responses to TB. We hypothesize that evaluating these responses in former CAMELIA patients cured of TB and on stable ART in a TB endemic environment will lead to identification of novel antigens important for protective responses and future vaccine development. Host biomarkers of TB infection, TB-IRIS and TB/HIV co-infection and linked clinical outcomes are lacking. Using RNA microarrays, we will determine signatures associated with TB co-infection, TB-IRIS, and antigen specific TB responsiveness. We hypothesize that this analysis in this extremely well-characterized patient cohort will provide robust and novel biomarkers of TB co- infection, containment of TB disease, and protective responses associated with in vitro assays. Finally, using archived PBMC, from TB+/ HIV+ patients from CAMELIA or TB-/HIV+ patients with similar baseline characteristics who began ART at the same time, we will test the hypothesis that TB co-infection and TB-IRIS modulate HIV reservoir tropism after ART initiation the months after ART initiation and years later and potentially also influence reservoir size. Findings from these experiments will be of great value for improving both treatment of TB/HIV co-infection and our general understanding of the host immune response to TB/HIV as well as providing the first evidence indicating that TB co-infection can affect the composition of the HIV reservoir.
描述(由申请人提供):
虽然结核分枝杆菌(MTb)感染是艾滋病死亡的最大原因,也是全球艾滋病毒相关肺部疾病的主要原因,但对结核病合并感染如何影响长期免疫重建或HIV-1储库知之甚少。柬埔寨抗逆转录病毒药物(ART)早期与晚期引入(CAMELIA)随机临床试验显示,早期开始ART(TB治疗开始后2周与8周时晚期ART)
周),导致CD 4 + T细胞计数<200个细胞/mm 2的TB+/HIV+患者的死亡率显著降低(34%),生存益处持续至少3年。我们在嵌套子研究中检查了CAMELIA随机临床试验中TB+/HIV+个体的T细胞应答的初步数据,表明TB和TB相关免疫重建综合征(TB-IRIS)导致治疗开始后至少8个月T细胞区室发生深刻变化。例如,TB共感染和TB-IRIS与大量T细胞活化(包括升高的CCR 5 + T细胞)相关,并导致对中枢记忆(TCM)(CD 62 L + CD 45 RA-)CD 4 +T细胞(主要外周HIV储库组分和效应记忆)的比例的显著影响。在经历TB-IRIS的患者中,我们观察到与对照TB相关的T效应(TEM)(CD 62 L-CD 45 RA-)CD 4 +T细胞的相互扩增。此外,TB-IRIS患者的CXCR 3 + CCR 6 + CD 4 + T细胞升高,这被认为是介导了大部分的CD 4+抗TB反应,这些CXCR 3 + CCR 6 + CD 4 + T细胞在ART开始后至少8个月内保持显著升高。基于我们的初步数据,我们假设我们在TB-IRIS中观察到的不同细胞反应可能代表了对TB的重要保护性反应。我们假设,在结核病流行环境中,对治愈的前CAMELIA患者和稳定的ART患者的这些反应进行评估,将导致对保护性反应和未来疫苗开发重要的新抗原的鉴定。缺乏TB感染、TB-IRIS和TB/HIV合并感染的宿主生物标志物以及相关的临床结果。使用RNA微阵列,我们将确定与TB合并感染、TB-IRIS和抗原特异性TB反应相关的特征。我们假设,在这一非常充分表征的患者队列中的这种分析将提供TB共感染、TB疾病的遏制和与体外测定相关的保护性应答的稳健和新颖的生物标志物。最后,使用来自CAMELIA的TB+/ HIV+患者或同时开始ART的具有相似基线特征的TB-/HIV+患者的存档PBMC,我们将检验以下假设:TB合并感染和TB-IRIS在ART开始后数月和数年后调节ART开始后的HIV储库嗜性,并且还可能影响储库大小。这些实验的发现对于改善TB/HIV合并感染的治疗和我们对TB/HIV的宿主免疫应答的一般理解以及提供表明TB合并感染可以影响HIV储库的组成的第一个证据将具有重要价值。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A Role for IFITM Proteins in Restriction of Mycobacterium tuberculosis Infection.
- DOI:10.1016/j.celrep.2015.09.048
- 发表时间:2015-11-03
- 期刊:
- 影响因子:8.8
- 作者:Ranjbar S;Haridas V;Jasenosky LD;Falvo JV;Goldfeld AE
- 通讯作者:Goldfeld AE
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANNE GOLDFELD其他文献
ANNE GOLDFELD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANNE GOLDFELD', 18)}}的其他基金
Discovery of novel regulatory territories in the TNF/LT locus
TNF/LT 基因座中新调控区域的发现
- 批准号:
10650771 - 财政年份:2022
- 资助金额:
$ 81.29万 - 项目类别:
Discovery of novel regulatory territories in the TNF/LT locus
TNF/LT 基因座中新调控区域的发现
- 批准号:
10408494 - 财政年份:2022
- 资助金额:
$ 81.29万 - 项目类别:
Immunity to TB in highly immunosuppressed HIV-infected and uninfected individuals
高度免疫抑制的艾滋病毒感染者和未感染者对结核病的免疫力
- 批准号:
9303303 - 财政年份:2016
- 资助金额:
$ 81.29万 - 项目类别:
Immune control mechanisms of TB latency in the setting of HIV co-infection
HIV合并感染情况下结核潜伏期的免疫控制机制
- 批准号:
9229528 - 财政年份:2016
- 资助金额:
$ 81.29万 - 项目类别:
Immunity to TB in highly immunosuppressed HIV-infected and uninfected individuals
高度免疫抑制的艾滋病毒感染者和未感染者对结核病的免疫力
- 批准号:
9205082 - 财政年份:2016
- 资助金额:
$ 81.29万 - 项目类别:
Immune control mechanisms of TB latency in the setting of HIV co-infection
HIV合并感染情况下结核潜伏期的免疫控制机制
- 批准号:
9115843 - 财政年份:2016
- 资助金额:
$ 81.29万 - 项目类别:
Immune control mechanisms of TB latency in the setting of HIV co-infection
HIV合并感染情况下结核潜伏期的免疫控制机制
- 批准号:
9028020 - 财政年份:2015
- 资助金额:
$ 81.29万 - 项目类别:
T CELL SUBSETS AND THEIR FUNCTION IN TB/HIV PARADOXICAL REACTIONS
T 细胞亚群及其在 TB/HIV 矛盾反应中的功能
- 批准号:
7753855 - 财政年份:2009
- 资助金额:
$ 81.29万 - 项目类别:
T CELL SUBSETS AND THEIR FUNCTION IN TB/HIV PARADOXICAL REACTIONS
T 细胞亚群及其在 TB/HIV 矛盾反应中的功能
- 批准号:
7554709 - 财政年份:2009
- 资助金额:
$ 81.29万 - 项目类别:
相似海外基金
Determining 4-Dimensional Foot Loading Profiles of Healthy Adults across Activities of Daily Living
确定健康成年人日常生活活动的 4 维足部负荷曲线
- 批准号:
2473795 - 财政年份:2024
- 资助金额:
$ 81.29万 - 项目类别:
Studentship
Developing a trunk function assessment for hemiplegics. -For improving activities of daily living-
开发偏瘫患者的躯干功能评估。
- 批准号:
23K10540 - 财政年份:2023
- 资助金额:
$ 81.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Relation with the activities of daily living and the subjective values among people with social withdrawal
社交退缩者日常生活活动与主观价值观的关系
- 批准号:
23K16596 - 财政年份:2023
- 资助金额:
$ 81.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
CRII: RI: Understanding Activities of Daily Living in Indoor Scenarios
CRII:RI:了解室内场景中的日常生活活动
- 批准号:
2245652 - 财政年份:2023
- 资助金额:
$ 81.29万 - 项目类别:
Standard Grant
Sources of vulnerability among those using homecare despite having no limitations in Activities of Daily Living. An intersectionality analysis
尽管日常生活活动没有限制,但使用家庭护理的人的脆弱性来源。
- 批准号:
499112 - 财政年份:2023
- 资助金额:
$ 81.29万 - 项目类别:
Operating Grants
Association between Nursing Care and Prognosis and Activities of Daily Living in Acute Stroke patients by using Big Data.
利用大数据研究急性脑卒中患者的护理与预后和日常生活活动的关系。
- 批准号:
23K16412 - 财政年份:2023
- 资助金额:
$ 81.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of a model of nurses-occupational therapists collaborative practice on activities of daily living in elderly patients
护士-职业治疗师合作实践模式对老年患者日常生活活动的影响
- 批准号:
22K17540 - 财政年份:2022
- 资助金额:
$ 81.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Synergizing home health rehabilitation therapy to optimize patients’ activities of daily living
协同家庭健康康复治疗,优化患者的日常生活活动
- 批准号:
10429480 - 财政年份:2022
- 资助金额:
$ 81.29万 - 项目类别:
Assessing a Novel Virtual Environment that Primes Individuals Living with AD/ADRD to Accomplish Activities of Daily Living.
评估一种新颖的虚拟环境,该环境可以帮助 AD/ADRD 患者完成日常生活活动。
- 批准号:
10668160 - 财政年份:2022
- 资助金额:
$ 81.29万 - 项目类别:
Synergizing home health rehabilitation therapy to optimize patients’ activities of daily living
协同家庭健康康复治疗,优化患者的日常生活活动
- 批准号:
10621820 - 财政年份:2022
- 资助金额:
$ 81.29万 - 项目类别: